Filing Flows › Comparisons › FBIO vs XLO
Fortress Biotech vs Xilio Therapeutics: FBIO and XLO compared
Fortress Biotech is the larger company: $18.7M of revenue in its latest quarter (Q2 2026) against $18.7M for Xilio Therapeutics (Q2 2026). Xilio Therapeutics is growing faster (+131% against +14% a year earlier). Xilio Therapeutics is more profitable, with an operating margin of -18.7% against -53.5%.
Where the money goes: FBIO and XLO
Fortress Biotech (FBIO) · Q2 2026
Fortress Biotech, Q2 2026: revenue $18.7M (+14% year over year), operating margin -53.5%, net earnings $602K, operating cash flow −$59.3M. The chart follows the revenue to costs, profit and cash.
Xilio Therapeutics (XLO) · Q2 2026
Xilio Therapeutics, Q2 2026: revenue $18.7M (+131% year over year), operating margin -18.7%, net loss $6.4M, operating cash flow −$18.8M. The chart follows the revenue to costs, profit and cash.
| Fortress Biotech (FBIO) | Xilio Therapeutics (XLO) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $18.7M | $18.7M |
| Revenue growth, Y/Y | +14% | +131% |
| Operating margin | -53.5% | -18.7% |
| Net earnings | $602K | −$6.4M |
| Net margin | 3.2% | -34.1% |
| Operating cash flow | −$59.3M | −$18.8M |
Where the revenue comes from
Fortress Biotech
- Journey: $18.5M (99%)
- Fortress: $208K (1%)
Questions
Which is bigger, Fortress Biotech or Xilio Therapeutics?
Fortress Biotech is the larger company: $18.7M of revenue in its latest quarter (Q2 2026) against $18.7M for Xilio Therapeutics (Q2 2026).
Is Fortress Biotech or Xilio Therapeutics growing faster?
Xilio Therapeutics is growing faster (+131% against +14% a year earlier).
Which is more profitable, Fortress Biotech or Xilio Therapeutics?
Xilio Therapeutics is more profitable, with an operating margin of -18.7% against -53.5%.
More: Fortress Biotech earnings · how Fortress Biotech makes money · Xilio Therapeutics earnings · how Xilio Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.